Your SlideShare is downloading. ×
Sean Ekins cv
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Sean Ekins cv


Published on

curriculum vitae

curriculum vitae

Published in: Health & Medicine

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Sean Ekins [email_address] Collaborations In Chemistry Resume
  • 2. Experience
    • Over 14 years of applied pharmaceutical company experience
    • Computational ( in silico ) drug discovery, QSAR and pharmacophore application, systems biology applied to pathway and biomarker discovery, in vitro methods, drug-drug interactions and computational ADME/TOX.
    • Successfully obtained NIH SBIR phase I and II grant funding as a principal investigator at different companies.
    • Valuable start-up company experience leading and managing teams of international scientists and collaborators, directing technology development and scientific research .
  • 3. Key Academic Qualifications
    • Nottingham Trent University
      • HND Science (Applied Biology)
    • University of Aberdeen
      • M.Sc. Clinical Pharmacology
      • Ph.D. Medicine and Therapeutics (Clinical Pharmacology)
      • D.Sc. Science
  • 4. Key Positions – Diversity of Experience
    • Post doc - Eli Lilly
      • 1996-1998
    • Research Scientist – Pfizer
      • 1998-1989
    • Senior Computational Chemist – Eli Lilly
    • 1999- 2001
    • Associate Director, Computational Drug Discovery - Concurrent Pharmaceuticals
      • 2001- 2004
    • Vice President, Computational Biology
      • 2004- 2006
    • Senior Consultant, Collaborations in Chemistry
      • 2007 - present
  • 5. Adjunct Positions
    • Adjunct Professor, Robert Wood Johnson Medical School, University of Medicine and Dentistry New Jersey, July 2007-present.
    • Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland. MD, Jan 2005-present.
  • 6. Leadership Competencies
    • Collaboration and influencing: An outward facing scientist able to collaborate for mutual success and deliver on milestones.
    • Team leadership: An experienced cross-functional leader with effective communication skills.
    • Commercial orientation: Vast experience from pharma and biotech collaborations at identifying and obtaining opportunities for funding and applying leading edge technologies.
    • Results orientation: An intellectual and scientific risk taker who delivers beyond expectations.
    • Strategic orientation: Possesses a broad perspective of drug discovery and development.
  • 7. Strengths
    • Research innovation for drug discovery
      • Computational ADME/Tox Pioneer
      • Pharmacophore building expert
      • Broad cheminformatics skills for drug discovery
      • Technology development – e.g. MetaDrug which brought cheminformatics and systems biology together as an award winning commercial product
    • Writing papers and book chapters– over 150 since 1995
      • Many with over 100 citations
      • Web of Science h-factor = 33 (whatever value that has!)
    • Writing grants that get funded – 5 NIH grants to date as PI
    • Book Series editing for Wiley
    • Scientific Visionary – advocate of collaboration for over a decade
  • 8. Consulting For Clients
    • Collaborative Drug Discovery
      • BMGF funded grant on TB
      • STTR funded project
    • Merck
    • Longevica Pharmaceuticals
    • Ardelyx Pharmaceuticals
  • 9. Key Papers in 2010
    • Ekins S , Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol BioSyst In Press 2010.
    • Rishi R. Gupta, Gifford, EM, Liston T, Waller CL, Hohman M, Bunin BA and Ekins S , Using open source computational tools for predicting human metabolic stability and additional ADME/Tox properties, Drug Metab Dispos, In Press, 2010.
    • Ekins S and Williams EJ, When Pharmaceutical Companies Publish Large Datasets: An Abundance of riches or fool’s gold?, Drug Disc Today, In Press 2010.
    • Ekins S , Gupta R, Gifford E, Bunin BA, Waller CL, Chemical Space: missing pieces in cheminformatics, Pharm Res, In Press 2010.
    • Kortagere S, Krasowski MD, Reschly EJ, Venkatesh M, Mani S and Ekins S , Evaluation of Computational Docking to Identify PXR Agonists in the ToxCastTM Database Env Health Perspect, In Press 2010.
    • Ekins S , Honeycutt JD and Metz JT, Evolving molecules using multi-objective optimization: applying to ADME/Tox, Drug Disc Today, 15: 451-460, 2010.
    • Arnold RJG and Ekins S , Time for cooperation in health economics among the modeling community, PharmacoEconomics, 28(8):609-613, 2010.
    • Ekins S . and Williams AJ, Reaching out to collaborators: crowdsourcing for pharmaceutical research, Pharm Res, 27: 393-395, 2010.
    • Ekins S and Williams AJ, Precompetitive Preclinical ADME/Tox Data: Set It Free on The Web to Facilitate Computational Model Building to Assist Drug Development. Lab On A Chip, 10: 13-22, 2010.
    • Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C and Ekins S , Integrated In Silico- In vitro strategy for addressing Cytochrome P450 3A4 time dependent inhibition, Chem Res Toxicol, 23: 664-676, 2010.
    • Ekins S , Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Hohman M and Bunin BA, A Collaborative Database and Computational Models for Tuberculosis Drug Discovery, Mol BioSyst, 6: 840-851, 2010.
  • 10. Books I have edited since 2006
  • 11. Editorial Positions
    • Associate Editor: Journal of Pharmacological and Toxicological Methods, since Jan 2001
    • Editorial Board: Drug Metabolism and Disposition, since 2003, Drug Discovery Today, since 2005, The Open Drug Delivery Journal 2007-2009, Current Drug Metabolism 2007-2009, Drug Metabolism Letters since 2007-2009. Pharmaceutical Research (Editor of Reviews) since 2009, Mutation Research-Reviews since 2009, The ChemSpider Journal of Chemistry 2009.
    • Editorial Advisory Board: Pharmaceutical Research, 2006-2008
  • 12. Grants
    • NIH Grants
    • 2R44GM069124-02 In Silico Assessment of Drug Metabolism and Toxicity, SBIR phase II (principal investigator) Funded (~$750,000 total cost) from 08/01/05 to 08/01/07.
    • 1R43NS061376-01 Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases, SBIR phase I (principal investigator) Funded ($124,425 total cost) from 10/01/07 to 03/31/2008
    • 1R43CA130183-01A1 Computer-Aided Design, Synthesis, And Testing Of A Novel Family Of Triazole-Based Anticancer Therapeutics, SBIR phase I (principal investigator) Funded (Total cost $114,818) From 05/01/08- 10/31/08
    • 1R43AI078763-01A1 Development of an Inhibitor of Toxoplasma gondii, NIAID Advanced Technology SBIR (principal investigator on proposal submitted then replaced upon leaving company) Funded (Total cost $638,000)
    • 1R41AI088893-01 Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic based pathway analysis, STTR phase I (Principal Investigator) Funded (Total cost $149,382) 07/01/11 – 06/30/11
    • European Grants
    • Part of the consortia for the framework grant More Medicines for Tuberculosis
    • Specific Programme “Cooperation” – Theme "Health"
    • Call identifier: FP7-HEALTH-2010-single-stage
    • Proposal No: 260872
    • Acronym: MM4TB
  • 13. Research Interests
    • Collaboration
    • Nuclear receptors (PXR, FXR, LXR, VDR modeling)
    • P450 modeling
    • Transporter modeling
    • hERG modeling
    • Crowdsourcing